dupilumab biosimilar
/ United Laboratories
- LARVOL DELTA
Home
Next
Prev
1 to 1
Of
1
Go to page
1
April 22, 2026
UNITED LABORATORIES…announced that the atopic dermatitis indication for the dupilumab biosimilar injection developed by its wholly owned subsidiary, Zhuhai United, has obtained implied approval for clinical trials from the National Medical Products Administration of China.
(iis.aastocks.com)
New trial • Atopic Dermatitis
1 to 1
Of
1
Go to page
1